

Request Information

Permalink

# Anti-Cxcr6 Treatment For Myocarditis

Tech ID: 34449 / UC Case 2025-118-0

## INVENTION NOVELTY

## VALUE PROPOSITION

## TECHNOLOGY DESCRIPTION

Researchers at UCSF have developed a novel tantibody treatment to address myocarditis, a serious cardiac inflammatory condition that currently has no FDA-approved treatments. The technology is in pre-clinical development, with successful proof-of-concept studies demonstrating that the treatment can rescue cardiac inflammation in mouse models of immune checkpoint inhibitor-induced myocarditis. What makes this approach particularly innovative is its targeting of a subset of T-cells that have been identified as key mediators of cardiac inflammation in both human patients and animal models. While other companies may be exploring similar therapies for different indications, this represents the first known application of this therapeutic mechanism specifically for cardiac inflammation, potentially offering a revolutionary treatment option for patients suffering from myocarditis and related inflammatory heart conditions.

## APPLICATION

## LOOKING FOR PARTNERS

## STAGE OF DEVELOPMENT

## RELATED MATERIALS

## DATA AVAILABILITY

## PATENT STATUS

Patent Pending

### CONTACT

Jessica Chan  
[jessica.chan2@ucsf.edu](mailto:jessica.chan2@ucsf.edu)  
tel: .



### OTHER INFORMATION

#### KEYWORDS

Myocarditis, Cardiovascular, Antibody

#### CATEGORIZED AS

- ▶ **Biotechnology**
- ▶ Health
- ▶ **Medical**
- ▶ Disease: Cardiovascular and Circulatory System
- ▶ New Chemical Entities, Drug Leads

#### RELATED CASES

2025-118-0

600 16th St, Genentech Hall, S-272,  
San Francisco,CA 94158

<https://innovation.ucsf.edu>  
Fax:

© 2025, The Regents of the University of  
California  
[Terms of use](#) [Privacy Notice](#)